Predilife: Sales Up in the First Half of 2026, Cash Runway Only Until February 2027
Predilife published its half-year accounts on 10 November 2026, which combine two distinct sets of facts. Revenue for the first half of 2026 rose from €392,773 to €576,547, and the net loss was reduced. At the same time, cash, including established receivables from the French Treasury, stands at approximately €100k.
The growth in activity comes while the company is subject to a judicial reorganisation procedure, monitored by the Commercial Court of Créteil. The published accounts should therefore be read both from the perspective of commercial activity and from that of the company's financing capacity.
A Reduced Net Loss Following the Refocusing on MammoRisk
The rise in sales is accompanied by an improvement in results. According to the press release, the net loss was reduced following the refocusing of the business on MammoRisk. This is the only explanatory factor put forward by the company for this change.
These half-year accounts were approved by the board of directors on 10 November 2026 and were not audited by the statutory auditors. The half-year financial report as of 30 June 2026 was made available to the public the same day on the company's website.
Listed on Euronext Growth, Predilife develops tests predicting the risk of pathologies, applying artificial intelligence methods to clinical and genetic medical data. The stated objective is to offer a personalised monitoring protocol and earlier identification of diseases.
A Cash Horizon Until February 2027, Under Judicial Reorganisation
According to Predilife, its cash gives it a horizon until February 2027. The amount considered includes established receivables from the French Treasury: part of the resources taken into account therefore corresponds to sums owed by the State, and not to cash already collected.
On the judicial front, the company is subject to a judicial reorganisation procedure. The Commercial Court of Créteil renewed the observation period for six months at the hearing of 4 November 2026.
The rise in revenue and the reduction in the net loss thus coexist with a level of cash which, according to the company's own indications, covers its needs until early 2027.
DenSeeRisk: New FDA Filing Planned in Approximately Two Months
The third item in the publication concerns DenSeeRisk, whose approval application with the FDA is under review. The company received an initial response requesting technical clarifications or corrections, notably regarding cybersecurity.
Predilife states that a new filing incorporating these changes will be submitted in approximately two months. The approval process thus remains at the review stage, as the company still has to complete its file.
The press release therefore combines growing activity and a reduced net loss following the refocusing on MammoRisk with a financial situation whose deadlines are set by the company and by the court: the announced cash horizon and the renewed observation period.
